CryoPort (CKX) Q3 2026 Earnings Report

The call was strongly positive. Cryoport reported 14% revenue growth, 18% growth in Life Sciences Services, 20% growth in commercial cell and gene therapy activity, a record clinical trial pipeline, positive adjusted EBITDA for the second consecutive quarter, and increased full-year revenue guidance. Management also highlighted expanding bioservice capabilities, continued MVE demand, and a favorable cell and gene therapy market outlook. The main challenges were delayed applications, limited China growth, cyclical animal health demand, selective margin impact from facility expansions, and conservative fourth-quarter guidance.

Cryoport raised full-year 2026 revenue guidance to $197 million to $199 million, representing 12% growth year-over-year, with “upside potential for that as well”; the implied Q4 revenue range was $50 million to $52 million, with guidance described as “prudent,” “conservative,” and reflecting a “minimum,” and new approvals are “really not baked into the guidance.” For the remainder of 2026, the company expects “5 possible BLA/MAA application filings,” “2 potential new therapy approvals,” and “1 additional supplemental approval for geographic expansion,” with 1 approval scheduled in November and 1 in December, while 4 applications were pushed into 2027. MVE is expected to deliver “solid mid-single-digit growth on a continued basis,” China represents “about 3% to 4%” of total revenue with “no significant growth,” and biostorage and bioservices are expected to continue as a “double digit grower.” Long-term goals are 55% gross margin and 30% adjusted EBITDA, with “further EBITDA margin expansion in 2027 and beyond,” while cell and gene therapies are expected to grow at a “6 year 30-34% CAGR” from $10.2 billion in 2025 to roughly $60 billion in 2030.